Cellectar Biosciences Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$22.3MTTM through 30 Jun 2026
Free Cash Flow -$19.5MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-187.5%ROA
Balance Sheet Health
Debt / Equity0.49x
Current Ratio1.90x
Net Debt-$6.7Mnet cash position
Cash & Equivalents$34M
Quality Metrics
Altman Z-Score-10.04
Piotroski F-Score3 / 9
Earnings-Beat Rate100.0%
Multi-Year Trend
Diluted EPS-$2.21TTMFY2025: $-8.35
Dividend
No dividend
Capital Allocation
R&D Spend$13.2M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.